Beyond cardiovascular medicine: potential future uses of icosapent ethyl.
Beyond cardiovascular medicine: potential future uses of icosapent ethyl.
复制标题
DOI:
10.1093/eurheartj/suaa119
复制
发表时间:
2020-10
期刊:
影响因子:
--
通讯作者:
Toth PP
中科院分区:
文献类型:
--
作者:
Bhatt DL;Hull MA;Song M;Van Hulle C;Carlsson C;Chapman MJ;Toth PP
The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree. While the cardiovascular protective properties of this compound are now proven, several other potential uses are being actively explored in clinical studies. These areas of investigation include cancer, inflammatory bowel disease, infections, Alzheimer’s disease, dementia, and depression. The next decade promises to deepen our understanding of the beneficial effects that EPA may offer beyond cardiovascular risk reduction.
登录
查看更多内容
DOI:
10.4049/jimmunol.1100150
发表时间:
2011-10-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Campbell EL;Serhan CN;Colgan SP
通讯作者:
Colgan SP
影响因子:
24
作者:
Bhatt, Deepak L.;Steg, Ph Gabriel;Ballantyne, Christie M.
通讯作者:
Ballantyne, Christie M.
影响因子:
39.3
作者:
Boden, William E.;Bhatt, Deepak L.;Luescher, Thomas F.
通讯作者:
Luescher, Thomas F.
DOI:
10.1016/j.plefa.2014.05.007
发表时间:
2015-01-01
影响因子:
3
作者:
Chen, Chuck T.;Bazinet, Richard P.
通讯作者:
Bazinet, Richard P.
DOI:
10.1016/s1474-4422(16)30029-1
发表时间:
2016-08
期刊:
The Lancet. Neurology
影响因子:
--
作者:
Arvanitakis Z;Capuano AW;Leurgans SE;Bennett DA;Schneider JA
通讯作者:
Schneider JA